In 2025, the Consortium for Personalised Breast Cancer Prevention was established to implement a practical model for personalised breast cancer prevention in the United Kingdom. This initiative enables women to access personalised breast cancer risk assessments and tailored screening programmes through our partners.
Personalised Breast Cancer Prevention is a telemedicine service offered in collaboration with the consortium partners Breast Awareness Clinic, Prevent Breast Cancer, and Antegenes Ltd.
- The service is supported by Prevent Breast Cancer – the UK charity committed solely to predicting and preventing breast cancer.
- The service is organised and coordinated by Antegenes Ltd, UK. Antegenes is a an ISO 13485-certified European cross-border healthcare service provider headquartered in Estonia. Its personalised cancer prevention is offered as a cross-border healthcare service with healthcare licences L05386 & L04683.
- Polygenic risk score analysis is performed using the CE-IVD certified AnteBC test (registered in the UK MHRA Registry GMDN code: 59918) provided by Antegenes.
- The Breast Awareness Clinic provides optional post-test consultations and support for patients seeking personalised medical guidance.
- Professor Gareth Evans is a Consultant Geneticist with a national and international reputation for his work in cancer genetics, particularly breast cancer. He is an important opinion leader on hereditary breast cancer and cancer syndromes. Prof Evans offers optional additional consultations at The Christie Private Care, Manchester.